Companies · Pharmaceuticals

Salarius Pharmaceuticals, LLC

Holladay · Pharmaceuticals

Diligence memoA one-page analyst read on Salarius Pharmaceuticals, LLC — recommendation, valuation, rhythm, risks.
$1.0M
Total raised · real
3
Rounds
5.9×
Latest step-up
Top 81%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Thu Apr 30 2015 00:00:00 GMT+0000 (Coordinated Universal Time)

Salarius Pharmaceuticals, LLC looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 3.23× the median modeled value of Pre-Seed Pharmaceuticals companies in 2013–2015 (87 peers) — value vs value, same stage and era.
Dormant
  • Last raise 11.2 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Salarius Pharmaceuticals, LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
13.3 yr record
Peak capital year was 2015 with $775K across 1 filings.
Market position
ahead of 20% of Pharmaceuticals peers
Capital scale is ahead of 20% of Pharmaceuticals peers; modeled value is above 37% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2015: $775K across 1 filings.
  • Largest single filing was $775K on 2015-04-30.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Salarius Pharmaceuticals, LLC is one of 1613 Pharmaceuticals companies tracked from Holladay. By capital raised it ranks in the long tail (ahead of 20% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
3
Investors (latest)
2015-04-30
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$13M$25M$38M$50MPre-Seed · 2013-03-21 Raised $108K (real) Modeled valuation $5.1M (est)$108K$5.1MPre-Seed2013Pre-Seed · 2014-03-22 Raised $132K (real) Modeled valuation $6.2M (est)$132K$6.2MPre-Seed2014Pre-Seed · 2015-04-30 Raised $775K (real) Modeled valuation $37M (est)$775K$37MPre-Seed2015+$132K+$775KCumulative $1.0M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$108K · 2013
Pre-Seed extension$132K · 2014
Pre-Seed extension$775K · 2015

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$36.7M
Base estimate est.
$434K
Conservative case
$415.7M
Upside case
$4.3M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $5.1M · 2013-03-212013Pre-Seed · modeled $6.2M · 2014-03-22Pre-Seed · modeled $36.7M · 2015-04-302015
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
25%
Survival probability
10% low · 46% high
1.80×/yr
Annual markup
2.44×/yr upside case
6.0 yr
Elapsed time used
11.2 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
13 mo
Avg between rounds
$481K/yr
Capital velocity
13.3 yr
On record since
2013
First round
3
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.1× of median
This company$1.0M
Sector median$8.1M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 1.8× above median
This company$775K
Sector median$421K
Modeled value — vs sector median (estimate, all stages) 0.5× of median
This company$36.7M
Sector median$76.1M

Raised more than 20% of sector peers (real $). Modeled value above 37% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #10 of 87.

This companyCohort peer
$10.0M$100.0M$100K$1.0M$10.0MCapital raised (log)IPM Safety Services, Inc. · Pre-Seed Raised $1.0M · modeled $47.3M (est)Scioderm, LLC · Pre-Seed Raised $1.0M · modeled $47.3M (est)Chondrial Therapeutics, LLC · Pre-Seed Raised $1.6M · modeled $47.3M (est)OnCore Biopharma, Inc. · Pre-Seed Raised $1.0M · modeled $47.3M (est)VR1 Corp · Pre-Seed Raised $2.5M · modeled $42.6M (est)Maia Pharmaceuticals, Inc. · Pre-Seed Raised $845K · modeled $40.0M (est)Dolor Technologies LLC · Pre-Seed Raised $800K · modeled $37.8M (est)Sujana Biotech, LLC · Pre-Seed Raised $800K · modeled $37.8M (est)Ucb S.A. · Pre-Seed Raised $788K · modeled $37.3M (est)Antivirus Therapeutics, Inc. · Pre-Seed Raised $743K · modeled $35.1M (est)Lobesity Investors LLC · Pre-Seed Raised $723K · modeled $34.2M (est)Salarius Pharmaceuticals, LLC (this company) Raised $1.0M · modeled $36.7M (est)Salarius Pharmaceuticals, LLC
CompanyStageRaised · realValue · estvs peer med.
IPM Safety Services, Inc.Pre-Seed$1.0M$47.3M4.17×
Scioderm, LLCPre-Seed$1.0M$47.3M4.17×
Chondrial Therapeutics, LLCPre-Seed$1.6M$47.3M4.17×
OnCore Biopharma, Inc.Pre-Seed$1.0M$47.3M4.17×
VR1 CorpPre-Seed$2.5M$42.6M3.75×
Maia Pharmaceuticals, Inc.Pre-Seed$845K$40.0M3.52×
Dolor Technologies LLCPre-Seed$800K$37.8M3.33×
Sujana Biotech, LLCPre-Seed$800K$37.8M3.33×
Ucb S.A.Pre-Seed$788K$37.3M3.28×
Salarius Pharmaceuticals, LLC this companyPre-Seed$1.0M$36.7M3.23×
Antivirus Therapeutics, Inc.Pre-Seed$743K$35.1M3.09×
Lobesity Investors LLCPre-Seed$723K$34.2M3.01×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$108K2013-03-21$602K$5.1M90%
Pre-Seed$132K2014-03-22$731K$6.2M90%
Pre-Seed$775K2015-04-30$4.3M$36.7M85%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$108K2013-03-21
    • First recorded raise — entered as Pre-Seed.
    • 8 investors on this round.
  2. Pre-Seed$132K2014-03-22
    • Raised 12 mo later, in step with the ~13 mo sector norm.
    • Round roughly the size of the prior one.
    • 7 investors on this round.
  3. Pre-Seed$775K2015-04-30
    • Raised 13 mo later, in step with the ~13 mo sector norm.
    • Round 5.9× larger than the prior — scaling up.
    • 3 investors on this round.
Intelligence
2016 ~Q2
Modeled next raise · ~13mo cadence
$2.3M
Modeled next size est.range $1.5M$3.7M
5.9×
Last step-up
$481K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
David Bearss4 other2015-04
David J. Arthur2 other2013-03
David J. Bearss2 other2013-03
David Arthur1 other2015-04
Jonathan Northrup1 other2015-04
Sunil Sharma1 other2015-04
Jonathan J. Northrup2013-03
Sunil J. Sharma2013-03
Registry & provenance

Salarius Pharmaceuticals, LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1661178
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Beta Cat Pharmaceuticals, Inc.PharmaceuticalsSeed$5.5M$98.9Mnetwork2 shared operators · same sector
Armgo Pharma IncPharmaceuticalsPre-Seed$1.0M$47.3Msame sector · same stage
Blake Insomnia Therapeutics, Inc.PharmaceuticalsPre-Seed$1.0M$47.3Msame sector · same stage
Elion Oncology, Inc.PharmaceuticalsPre-Seed$1.0M$47.3Msame sector · same stage
Enfuego Therapeutics, Inc.PharmaceuticalsPre-Seed$1.0M$27.0Msame sector · same stage
Entopica Therapeutics, Inc.PharmaceuticalsPre-Seed$1.0M$47.3Msame sector · same stage
Essentia Pharma Florida, LlcPharmaceuticalsPre-Seed$1.0M$47.3Msame sector · same stage
Essentia Pharma Socal, LlcPharmaceuticalsPre-Seed$1.0M$47.3Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Salarius Pharmaceuticals, Inc.BiotechnologySeries B$57.8M91%
Medexus Pharmaceuticals Inc.PharmaceuticalsPre-Seed$18.9M83%
Continuus Pharmaceuticals, Inc.PharmaceuticalsSeries A$154.9M83%
Synedgen, Inc.PharmaceuticalsSeries A$8.3M83%
Solaxa Inc.PharmaceuticalsPre-Seed$1.3M83%
Coeptis Pharmaceuticals, Inc.PharmaceuticalsSeries B$16.4M83%
Marinus Pharmaceuticals, Inc.PharmaceuticalsSeries B$21.0M82%
Harmony Biosciences II, Inc.PharmaceuticalsSeries D+$1.8B82%
Frequently asked
How much funding has Salarius Pharmaceuticals, LLC raised?
Salarius Pharmaceuticals, LLC has raised approximately $1.0M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Salarius Pharmaceuticals, LLC's estimated valuation?
Provath's modeled valuation for Salarius Pharmaceuticals, LLC is approximately $36.7M (modeled range $434K–$415.7M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Salarius Pharmaceuticals, LLC at?
Salarius Pharmaceuticals, LLC's latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Thu Apr 30.
What does Salarius Pharmaceuticals, LLC do and where is it based?
Salarius Pharmaceuticals, LLC operates in the Pharmaceuticals sector, based in Holladay.
Explore related

See where Salarius Pharmaceuticals, LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Salarius Pharmaceuticals, LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.